Autopsy report · NCT03208322

Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults

Cause of deathFunding or business Automatic label, confidence 0.5, unverified. How labels are made.

“There was a change in the strategy to complete the RMP with HA.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Sponsor: Bristol-Myers Squibb
Sponsor type: Industry
Conditions: Hepatitis C
Interventions: Non-Interventional
Participants: 0
Sites: 2
Countries: Mexico

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.